Abiomed mentioned cautiously by Potomac Research Potomac Research believes the odds have increased that the DMS will open up a national coverage decision, or NCD, for Abiomed's Impella product by year end. The firm believes someone, likely a Medicare Administrative Contractor, requested the NCD and that the news should be viewed as a negative.
News For ABMD From The Last 14 Days
Check below for free stories on ABMD the last two weeks.
Subscribe for More Information